Pacific Biosciences of California, Inc. Announces First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Adobe CFO Dan Durn to depart company in June 2026
Pacific Bio (PACB) Tops Q1 EPS by 2c
April 21, 2016 4:29 PM EDTPacific Bio (NASDAQ: PACB) reported Q1 EPS of ($0.23), $0.02 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $19.1 million versus the consensus estimate of $18.02 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
... More